SACT 1

  • SACT 1 - Inaugural Event 6th Jan 2023

    SACT1 which was the Inaugural SACT event was held in two sessions: Successes and Challenges of Cellular Immunotherapy and Bridging Cell Therapy Process Development & cGMP Manufacturing which was a huge successfully conducted event and one of a kind in the Asia pacific region in the context of Cell therapy.Moving up from our success in first SACT, our theme for this.

International Speaker Talk Title Highlights
Dr. Nirali N. Shah
Cancer Research National Cancer Institute
CART Cell Therapy : Factor affecting Clinical Outcome in B Cell Malignancies A talk on different factors effects on B-cell malignancies already have a compromised or dysregulated immune system. Different approaches for overcoming those factors.
Dr. Rizwan Romee
Dana-Farber Cancer Institute
Next Generation Cell Therapies for Cancer : NK & CAR -NK Cells Modern way of developing CAR constructs contain one or more co-stimulatory domains which improve T-cell activation and persistence for treating of cancer cells.
Dr. Mingming Li
Cytiva
Pre-Clinical to Commercialization : A Systematic Platform and Pathway Based Approach for CAR-T Therapies CAR T cell therapy have been successful in treating of hematologic malignancies. In which targeting of CD19, a surface antigen expressed on precursor and mature B cells, can treat B cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clinical trials in which evaluating new CAR-T cell therapies against different types of cancers, detailing the latest trends in CAR-T cell development.
Dr. Mahender Rao
Stempeutics
"Off the shelf" Universal Cell therapy using iPSC-derived rejuvenated Immune cells for solid and liquid tumors iPS cells are delivered from own patients cells further use for creating the cells that has potential to replicate the tissue affected by disease. This technique helps for study different test related to drug efficacy, side effects, and toxicity and to develop new drugs and therapies.
National Speaker Talk Title Highlights
Dr. Arun Kumar Arunachalam
Christian Medical College, Vellore
Current Manufacturing methods for the large-scale production of Clinical-Grade Virus-Specific T Cells for phase I/II clinical trials The SB transposon/transposase are used to produce genetically modified CAR-T cells for phase I/II clinical trial, Transfected T cells are subsequently expanded on artificial antigen-presenting cells. The major advantage of using the SB system are clinical-grade plasmids which are simpler to produce, cost effectiveness Also cell products genetically modified with gamma retroviral or lentiviral vectors are also used in for manufacturing of CAR T-Cell.
Dr. Likhesh Sharma
Cytiva
Challenges of Process Development in Cell Therapy Products In cell therapy process challenging because of the difficulty of fully characterizing a living cell and obtaining relevant data in real time.
Dr. Kunapuli Kishore
Pulse Pharmaceuticals
Dr. T Rajkumar
Adyar Cancer Institute
Unlocking the Power of Collaboration to Fuel Cell Therapy Development in India The objective of this cooperative endeavour is to progress the domains of clinical investigation and advancement concerning mesenchymal stem cell and NK cell therapy. The collaboration represents a critical advancement in the search for cutting-edge medical treatments.
Dr. Rajiv Sarin
TATA Memorial Hospital
Dr. Balaram Rao
Aurigene Discovery Technologies
Dr. Madhvi Rao
BIRAC
Dr. Uday Kumar
Stempeutics
Robust and stringent Quality Control/Analytical Characterization for Cell Therapy Products - Streamlining Strategy from IND to Clinical Analytical development in cell therapy involves the development and optimization of methods and tools to evaluate the quality, safety, and efficacy of cell-based products.
Shalini Jatia
ImPaCCT Foundation
Celebrating Victory over Cancer "Hope" is the biggest annual event for Pediatric Cancer patients at Tata Memorial Centre. "Hope" as the word signifies, is a strong and positive belief of victory over. childhood cancer. It is a celebration to spread the message in the society and country that "Childhood Cancer is Curable".
Subscribe to our newsletter for updates

SACT 2025 CONFERENCE